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Splenic Artery Syndrome (SAS) has emerged as a controversial cause for graft ischemia in orthotopic liver
transplant (OLTx) recipients. A complex combination of factors including hepatic artery hypoperfusion
and portal hyperperfusion can result in SAS. Clinical and laboratory ﬁndings suggest graft ischemia but
are generally non-speciﬁc. Conventional angiography ﬁndings of hepatic artery hypoperfusion with early
and rapid ﬁlling of the splenic artery are suggestive of the diagnosis in the appropriate clinical setting.
Treatment involves proximal splenic artery embolization, surgical splenic artery ligation, or in extreme
cases, splenectomy. Most patients with SAS improve clinically following treatment. However, no ran-
domized control trials are available to compare treatment options. Identiﬁcation of at risk patients with
pre-operative CT scans and intra-operative ultrasound has been proposed by some and may allow for
prophylactic treatment of SAS.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Vascular complications, especially those related to the hepatic
artery, are well-recognized causes of graft failure in the early post-
operative period following OLTx. Hepatic Artery Thrombosis (HAT)
[1e3] and Hepatic Artery Stenosis (HAS) [4,5] may warrant revas-
cularization or in certain cases, re-transplantation [6,7]. Over the
past couple decades, Splenic Artery Syndrome (SAS) has emerged
as a controversial cause of hepatic artery hypoperfusion leading to
graft ischemia [8e10]. SAS describes a decrease in hepatic artery
blood ﬂow in the absence of HAS and HAT, and is commonly
associated with increased blood ﬂow through an enlarged splenicLTx, Orthotopic Liver Trans-
asound.
ena@gmail.com (S.N. Reddy).
by Elsevier Ltd. All rights reservedartery [8]. Consequences of SAS include early graft dysfunction and
biliary ischemia occasionally leading to re-transplantation [8e10].
Several studies have reported successful treatment of SAS and
functional restoration of the graft with splenic artery embolization
[11,12]. Other studies have stressed the importance of pre-
transplant evaluation and intervention to prevent SAS in an
attempt to reduce post-transplant complications and irreversible
graft dysfunction [13,14]. Our review summarizes the pathophysi-
ology, epidemiology, diagnosis and available treatment options,
and possible prevention strategies of SAS.
2. Pathophysiology
SAS is a poorly understood and controversial cause of non-
occlusive hepatic arterial hypoperfusion in OLTx recipients. The
entity was initially described by Manner et al., in 1991 as a true
arterial ‘steal’ resulting in preferential diversion of blood ﬂow away
from the hepatic artery and towards the splenic artery [8]. These.
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tional angiography demonstrating rapid and preferential ﬁlling of
either the splenic artery, or less commonly the gastroduodenal
artery (GDA), at the expense of the hepatic artery [8,15]. However,
in 2008, Quintini et al. proposed that portal venous hyperperfusion,
and not splenic artery steal, was primarily responsible for SAS [9].
Through the use of DUS, Quintini's group not only interrogated
dynamic changes in systemic blood supply to the liver but also
assessed changes in portal venous ﬂow. Their work suggested that
portal hyperperfusion caused sinusoidal injury in liver transplants
through two main mechanisms: 1) direct damaging effect of
elevated portal venous pressures and 2) hepatic arterial hypo-
perfusion caused by the hepatic artery buffer response (HABR) [9].
HABR refers to physiologic auto-regulation of the systemic and
splanchnic circulations of the liver with respect to maintaining
adequate hepatic blood ﬂow [16]. Adenosine, a strong vasodilator,
has generally been accepted as the key in this auto-regulatory
pathway [16]. It is hypothesized that adenosine is constantly
released into spaces surrounding hepatic arterioles and portal ve-
nules. When portal ﬂow decreases, there is decreased washout of
adenosine and increased adenosine concentration, leading to he-
patic arterial vasodilation and increased hepatic arterial ﬂow.
Conversely, in the setting of increased portal venous ﬂow, there is
accelerated washout of adenosine, leading to hepatic artery vaso-
constriction and decreased hepatic arterial ﬂow. The reason for
portal venous hyperperfusion in post-transplant patients is not
entirely clear. A discrepancy between the sizes of the transplant
liver relative to the portal vein, as seen in undersized split grafts
(also referred to as Small for Size Syndrome), has been implicated in
portal venous hyperperfusion [17].
Despite important observations made by Quintini's group, they
failed to prove causality and the pathophysiology of SAS remains
controversial. In 2012, Saad challenged the portal hyperperfusion
theory, arguing that increased portal venous ﬂowmay simply occur
in response to primary hepatic arterial hypoperfusion [10]. Saad
pointed out that treating SAS with GDA coiling in cases of GDA
‘steal’ was effective even though it had little impact on portal
venous perfusion [10]. Saad concluded that while portal hyper-
perfusion and HABR are likely partly responsible for development
of SAS, no study has established causality as of yet and the hemo-
dynamics affecting liver transplant perfusion are complex and
multifactorial [10].
3. Epidemiology
The reported incidence of SAS in OLTx recipients ranges from
0.6% to 10.1% [18]. This wide range is related in part to whether SAS
is actually recognized as a post-transplant complication. Saad
contends that SAS is “probably under-recognized in certain in-
stitutions (particularly in the United States and Japan), and it is
probably over-diagnosed in others (particularly in Germany and
Austria)” [18]. Unfortunately, little data is available to determine if
the risk of developing SAS depends on donor or recipient de-
mographics, which may vary by region and country.
4. Clinical presentation
SAS is a diagnosis of exclusion and should only be considered in
the absence of cellular rejection, infection, and toxicity. Clinical
features are non-speciﬁc ranging from a complete absence of
symptoms to acute graft failure [11,12]. Of the 113 patients with SAS
reported in the literature, 109 presented with transaminitis and
decreased hepatic function with or without biliary ischemia and
cholestasis (Table 1). Alanine/Aspartate Transaminases (AST/ALT)
levels can be as high as 1520/1275 U/L and gammaglutamyltranspeptidase levels are also often elevated [9,12,19]. Mild eleva-
tions in alkaline-phosphatase can be seen [11,12]. Nussler et al.
reported the varying degrees of liver dysfunction including 6 of 44
patients presenting with acute graft failure [12]. Occasionally,
recurrent ascites may be the primary presentation of graft
dysfunction. Patients usually have moderate to massive spleno-
megaly, which can further contribute to SAS [20,21]. Reports of
leukopenia and thrombocytopenia in SAS patients are other signs of
symptomatic hypersplenism [20,21]. If transplant biopsy is per-
formed, histological analysis often reveals mild inﬂammation in
SAS as opposed to the overt ﬁndings in acute rejection [22,23].
While SAS may develop any time from the immediate post-
operative period to 5.5 years following transplantation (Table 1),
the majority of patients are diagnosed within 2 months of trans-
plantation [10].
5. Diagnostic imaging
DUS is the initial test of choice for vascular and biliary compli-
cations in OLTx recipients given its availability, portability, and lack
of ionizing radiation. Evaluation of hepatic artery velocity, wave-
forms, and particularly vascular resistance is helpful for deter-
mining the cause of hypoperfusion. The resistive index (RI), deﬁned
by the formula; RI ¼ (Peak systolic velocity  End diastolic veloc-
ity)/Peak systolic velocity helps differentiate SAS fromHAS and HAT
with collateralization. In HAS, very high velocities can be seen at
the site of stenosis with a low resistance “parvus tardus” waveform
distal to the site of stenosis [21,24,25]. In contrast, patients with SAS
exhibit a high-resistance hepatic artery waveform with low dia-
stolic ﬂow or reversal of diastolic ﬂow. The RI in the hepatic artery
of patients with SAS is usually greater than 0.8 (Fig.1a) and diastolic
ﬂow may occasionally be reversed [9,11,26]. In addition, hepatic
artery systolic velocities are unusually low (<35 cm/s) [26]. How-
ever, these ﬁndings are non-speciﬁc and could be due to transient
graft edema, rejection, or infection [21,27,28]. Portal hyper-
perfusion can be seen with SAS but elevated portal velocities can
also be due to some degree of donor-recipient portal mismatch that
normalizes with time [29e31]. Although DUS ﬁndings of SAS are
not speciﬁc, DUS serves as an efﬁcient screening tool for excluding
other causes of graft ischemia, including HAT and HAS, as well as in
identifying patients who may beneﬁt from conventional
angiography.
While conventional ultrasound is very sensitive for HAT in the
acute post-operative period, non-occlusive conditions with very
low ﬂow may be missed [32,33]. Contrast Enhanced Ultrasound
(CEUS) improves the diagnostic yield for SAS and has corrected
erroneously diagnosed cases of hepatic artery thrombosis on
standard DUS [32,33]. Garcia-Criado et al. reported that all of the 8
patients found to have SAS in their study group initially had no ﬂow
detected in the hepatic artery on DUS, and would have initially
been misdiagnosed as having HAT [34]. Subsequent CEUS of the
hepatic artery in all 8 of these patients revealed low arterial peaks
and high-resistance waveforms, which was later conﬁrmed to
represent SAS [34]. Of note, DUS is operator dependent and while
CEUS may be more sensitive, the true sensitivity and speciﬁcity of
this modality in the diagnosis of vascular liver transplant compli-
cationsmay vary heavily on the operator and institution. Also, CEUS
has not yet been approved for use in the United States.
Multidetector computed tomographic angiography (CTA) is
another non-invasive modality that can be helpful in the diagnosis
of SAS. In a retrospective study, Kirbas, et al. discovered a statisti-
cally signiﬁcant difference in splenic artery sizes relative to hepatic
artery sizes in patients with SAS [35]. They reported that a splenic
artery size greater than 4 mm or greater than 150% the hepatic
artery size was associated with SAS [32,33].
Table 1
Clinical and diagnostic features of SAS.
Author (year published) Total number
of ptsa
Number
of ptsa with
SAS
Dominant clinical Feature(s)
(number of ptsa)
Diagnostic tools utilized Time to diagnosis
Rasmussen et al. (1997) 70 1 Not applicable Intraoperative DUS 0 days
Geissler et al. (2002) 165 1 Elevated liver enzymes
and decreased graft function (1)
Conventional angiography 29 days
Nussler et al. (2002) 1171 44  Elevated liver enzymes,
decreased liver
function, cholestasis (41)
 Acute graft failure (6)
 Biliary tract ischemia (12)
 Asymptomatic (3)
DUS and conventional angiography 3 weeks to 5.5 years
(Majority at 3 months)
Uﬂacker et al. (2002) 350 11 Elevated AST, ALT, GGTb (11) DUS and conventional angiography 1 to 60 days
Sevmis et al. (2006) 118 10 Elevated AST, ALT, bilirubin (10) DUS and conventional angiography 1 to 170 days
Kirbas et al. (2007) 198 10 Graft dysfunction, unspeciﬁed (10) Conventional angiography 4 days to 5 months
Grieser et al. (2010) 119 12 Graft dysfunction ± biliary
ischemia (12)
Conventional angiography e
Mogl et al. (2010) 455 24  Elevated liver enzymes
and elevated
bilirubin (20)
 Elevated bilirubin only (2)
 Refractory ascites (2)
 Low platelets (9)
DUS and conventional angiography 2 monthse52 months
Uslu et al. (2012) 210 20 Elevated liver enzymes
and clinical
deterioration (20)
DUS and conventional angiography 1 to 170 days
(Majority within 1 month)
Zhu et al. (2012) 247 8 Clinical suspicion of SAS,
unspeciﬁed
DUS, CEUS, conventional angiography 5 h to 7 months
Garcia-Criado et al. (2014) 675 7 Graft dysfunction, unspeciﬁed DUS, CEUS, conventional angiography 0 to 7 days
a Patients.
b Gamma-glutamyltransferase.
Fig. 1. 56-year-old male presenting one month post liver transplant with elevated LFTs. a. High resistance hepatic artery. DUS of a patient with SAS showing low peak systolic
velocity and end diastolic velocity and increased RI in the hepatic artery. b. Preferential splenic artery ﬂow. Conventional angiogram in a patient with SAS showing preferential blood
ﬂow into an enlarged splenic artery. c. Improved hepatic ﬂow after splenic artery embolization. Post-embolization conventional angiogram in a SAS patient demonstrating improved
hepatic artery and gastroduodenal artery perfusion. Mild spasm in the main hepatic artery and branches is noted. d. Normalization of hepatic artery waveform post splenic artery
embolization. Post-embolization DUS demonstrating improved hepatic arterial ﬂow, as evidenced by increased peak systolic velocity and end diastolic velocity in the hepatic artery
with decreased RI.
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increased spleen sizes, an enlarged spleen is often seen in cirrhotic
patients with portal hypertension prior to transplant. Patients with
well-functioning liver transplants can also have enlarged spleens
and be asymptomatic. Enlarged splenic size is therefore unlikely to
be of diagnostic signiﬁcance with respect to SAS in the post-
transplant period, particularly if observed in isolation [10].
Almost all studies of SAS rely on conventional angiography for
conﬁrmation of the clinically suspected diagnosis [11,12]. Findings
of SAS on conventional angiography include a patent hepatic ar-
tery (<50% stenosis) with sluggish ﬂow, delayed ﬁlling of intra-
hepatic arteries, and poor peripheral parenchymal perfusion with
early ﬁlling of an enlarged splenic artery (>150% the diameter of
the hepatic artery) (Fig. 1b). A more objective criteria proposed by
Uﬂacker et al. deﬁnes simultaneous visualization of the hepatic
artery and portal vein as a key ﬁnding of SAS [11]. This implies
that the contrast has passed through the splenic vasculature into
the intrahepatic portal vein, “catching up” with the contrast that
is still in the hepatic artery [11]. Much less commonly, an
enlarged gastroduodenal artery (GDA) may ﬁll preferentially
rather than the splenic artery. In these cases, the superior
mesenteric artery (SMA) should also be evaluated as GDA “steal”
may represent preferential collateral circulation from a severe
SMA stenosis [10].
Although conventional angiography is necessary in the diag-
nosis of SAS, no true gold standard imaging study exists. The
diagnosis is suspected based upon a constellation of clinical, labo-
ratory, and imaging ﬁndings after exclusion of more common
causes of graft dysfunction. Ultimately, the diagnosis of SAS is
conﬁrmed when increased hepatic arterial perfusion and improved
graft function occur after splenic artery embolization [34].
6. Treatment
Early treatment of SAS may rapidly stabilize liver function [11].
Less invasive interventional methods are preferred over surgery
owing to lower complication rates. Splenic artery embolization is
the most common successful interventional treatment for SAS [11].
Early attempts at treating SAS by coiling the distal splenic artery
were met with several complications, including sepsis, need for
splenectomy, graft failure, multi-organ failure, and ultimately death
[12]. Morbidity and mortality of coiling the distal splenic artery
may have been related to increased likelihood of splenic infarction
and abscesses [12]. Splenic artery coiling is now performed in the
proximal splenic artery with signiﬁcantly fewer complications.
More proximal placement of coils is thought to preserve collateral
ﬂow to the spleen [11]. A post embolization angiogram should be
performed to evaluate hepatic artery perfusion [11]. In successful
cases, the post embolization angiogram will show increased and
prompt hepatic artery ﬂow and increased liver parenchymal
enhancement in the late arterial phase (Fig. 1c) [11]. Post-treatment
DUS can conﬁrm increased hepatic arterial perfusion with
normalization of the hepatic artery waveform with or without
decrease in the RI (Fig. 1d).
A few case reports have discovered hepatic artery stenosis
during the angiogram following splenic artery coiling for SAS
[36,37]. In these cases, it is recommended to treat the hepatic
arterial stenosis with angioplasty and/or possible stent placement
[36,37]. However, it is important to note that the diagnosis of SAS
must be reconsidered in these cases as SAS is generally a diagnosis
that can only truly be made in the absence of anatomic hepatic
artery lesions.
The Amplatzer Vascular Plug is a relatively new occlusion device
with a mesh-like conﬁguration with conﬁrmed safety in occluding
vascular structures [32,38,39]. Its precise deployment andresistance tomigration favor its use inmedium to large vessels with
high ﬂow. The use of Amplatzer Vascular Plug is associated with
lower radiation exposure compared to that of coils. However, vessel
tortuosity and small caliber lumens may limit its use [40].
Other methods of splenic artery occlusion using balloon devices
have been described with documented doubling of hepatic artery
ﬂow on Quantitative-Digital Subtraction Angiography [41]. Partic-
ulate embolization using microcatheter techniques and embolic
materials such as polyvinyl alcohol, Gelfoam (Upjohn, Inc., Kala-
mazoo, MI), or other commercially available bland particulate
embolic products have been discussed as well. Usually two to three
sessions are required to sufﬁciently reduce the splenic volumewith
a decreased risk of splenic infarction and abscess formation.
Approximately 30e40% of the spleen is devascularized at each
session [18]. However, this technique may take time (months) to
reach the desired effect from a splenic steal standpoint [10].
Surgical options include splenic artery banding and splenec-
tomy but are employed only when interventional treatments are
not effective. Surgical banding has been employed in the treatment
of SAS but it increases morbidity in a group of high-risk surgical
patients [12]. Splenectomy is an effective therapeutic option for
patients with conﬁrmed SAS [12]. However, post-operative sepsis
and portal vein thrombosis are potential complications. Current
recommendations suggest splenectomy only for cases with addi-
tional pathology such as splenic artery aneurysm [12].
Outcomes for treatment of SAS are generally favorable, partic-
ularly with recent advances in technique (Table 2). Of the studies
reviewed, 148 patients were collectively diagnosed with SAS and
received treatment, which included splenic artery coil emboliza-
tion, splenic artery ligation, splenic artery banding, vascular plug
devices, intra-arterial papaverine injection, or splenectomy
(Table 2). Fifteen of these patients had signiﬁcant complications
related to distal splenic artery coiling, which was not seenwith mid
or proximal splenic artery coiling [12]. No complications of treat-
ment were recorded with the remaining patients. A majority of
patients treated for SAS improved clinically, which was measured
in different ways depending on the study and ranged from
normalization of liver function tests to improved hepatic arterial
perfusion (Table 2). Several studies did not provide objective data
for determining treatment effects. Mogl et al. reported that 6 of the
23 patients treated for SAS in their study subsequently required
splenectomy but they did not consider these cases to represent a
complication of the treatment [13]. Also, 2 of the patients treated
for SAS in their study required re-operation for biliary complica-
tions and 4 patients required long term endoscopic biliary inter-
vention for biliary ischemia [13]. These ﬁndings suggest that
proximal splenic artery coiling may not completely treat or reverse
complications of hepatic artery hypoperfusion in all cases.
Furthermore, many studies did not include long term clinical data
on patients with treated SAS. Although the available data suggest
that success rates of SAS treatment in the post-procedural period is
relatively high, long-term outcomes are largely unknown. Unfor-
tunately, available data are insufﬁcient to compare efﬁcacy of the
various treatment options for SAS. No randomized trials have been
reported.
7. Prediction and prevention of SAS
The study of Grieser et al. noted that CT-determined splenic
volumes greater than 829 mL had a 75% accuracy for prediction of
SAS [23]. Other studies describe CT measured splenic artery di-
ameters of over 4mm and differences of 6mmbetween splenic and
hepatic artery diameters as pre-operative predictors of patients
with SAS [13,14,35]. Thus it may be possible to pre-operatively
predict and intervene prior to the development of SAS related
Table 2
Treatment and outcomes in SAS patients.
Author
(year published)
Total ptsa Ptsa
with
SAS
Treatment (no. of ptsa) Ptsa with
clinical
improvement
Clinical features of ptsa
with SAS that were
treated (number of ptsa)
Unsuccessful
treatment
Complications
of treatment
Pre-intervention Post-intervention
(successfully treated ptsa)
Rasmussen
et al. (1997)
70 1 Surgical ligation of
steal artery (1)
1 Graft artery ﬂow on DUS
144 mL/min
Graft artery ﬂow
on DUS 525 mL/min
None reported None reported
Geissler
et al. (2002)
165 1 Splenectomy (1) 1 Ten-fold increase
in AST/ALT
Transaminases back
to baseline within 5 days
None reported None reported
Nussler
et al. (2002)
1171 44  Splenic artery coil
embolization (29)
 Splenic artery
banding (9)
 No treatment (3)
41  AST > 100 IU/L (27)
 Elevated GGTb >
200 IU/L (32)
 Bilirubin >2 mg/dL (27)
 Biliary tract
destruction (12)
 No symptoms (3)
Normalization of liver
function; No objective
data provided
Graft failure
(7 pts, all with
distal splenic
artery coiling)
 Portal vein
thrombosis (3)
 Sepsis
requiring
splenectomy (9)
 Sepsis with
death (5)
All of the above
patients had distal
splenic artery coiling
Uﬂacker
et al. (2002)
350 11 Splenic artery coil
embolization (11)
11 Elevated AST, ALT,
and GGTb
(no objective
data provided)
Correction of elevated
liver enzymes
(no objective
data provided)
None reported None reported
Sevmis
et al. (2006)
118 10  Splenic artery coil
embolization (8)
 Splenic artery
narrowed stent
placement (1)
 Left gastric artery
coil embolization (1)
10 Elevated AST, ALT,
bilirubin
(no objective data
provided)
Improved liver function
tests and liver enzymes
(no objective data
provided)
None reported None reported
Kirbas
et al. (2007)
198 8  Partial splenic
embolization (6)
 Splenic artery
narrowed stent
placement (1)
 Papaverin hepatic
artery infusion (1)
Not reported Not reported Not reported Not
reported
Not
reported
Grieser
et al. (2010)
119 12  Splenic artery coil
embolization (12)
Not reported Not reported Not reported Not reported None
reported
Mogl
et al. (2010)
455 24  Splenic artery (23)
and gastroduodenal
artery coil
embolization (1)
23  Mean AST
233.7 ± 227.8 IU/L
 Mean bilirubin
3.1 ± 2.3 mg/dL
 Mean AST
38.4 ± 28.8 IU/L
 Decrease in bilirubin
P < 0.001
 Recovery of platelets
P < 0.017
Not reported None
reported
Uslu
et al. (2012)
210 20 Splenic artery coil
embolization
or vascular plug (20)
20 Median peak systolic
velocity in
hepatic artery: 47 cm/s
Median peak systolic
velocity in hepatic artery:
65 cm/s (P < 0.05)
None reported None reported
Zhu
et al. (2012)
247 8 Splenic artery coil
embolization (8)
8  Hepatic artery
diameter: 2.5 ± 0.3 mm
 Portal vein velocity
962 ± 47 cm/s
 Portal vein volume
76 ± 6 cm/s
 Hepatic artery
diameter: 3.7 ± 0.5 mm
 Portal vein
velocity 851 ± 78 cm/s
 Portal vein
volume 55 ± 8 cm/s
None reported None reported
Garcia-Criado
et al. (2014)
675 7  Splenic artery
ligation (5)
 Amplatzer splenic
artery plug (2)
7 Elevated AST/ALT, poor
graft function,
unspeciﬁed
Clinical measures
not reported
None reported None reported
a Patients.
b Gamma-glutamyltransferase.
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prophylactic SAS treatment. The most common procedures per-
formed for prophylactic SAS treatment are intra-operative splenic
artery ligation or banding, and pre-operative splenic artery embo-
lization (Table 3). Other prophylactic treatment options include
aortohepatic bypass grafting and arcuate ligament division [42]
Only one randomized control trial has been reported, which
found that preoperative proximal splenic artery embolization in
patients with severe portal hypertension prevented post-transplanthepatic hypoperfusion and led to decreased operative time and
blood loss [28]. Mogl et al. also reported a decreased risk of com-
plications in patients who underwent SAS prophylaxis relative to
patients who were treated for SAS post-operatively. They argued
that even when SAS was recognized and treated promptly, out-
comes were better with prophylactic treatment [13]. Interestingly,
Mogl's group reported 2 patients who developed SAS despite pro-
phylactic splenic artery banding, suggesting that prophylactic
measures are not 100% effective in preventing SAS [13]. It should
Table 3
Prophylactic treatment of SAS.
Author
(year published)
Total ptsa Ptsa selected
to undergo
prophylaxis
Criteria for prophylaxis Prophylactic measures Post-treatment events
(number of ptsa)
Clinical outcomes
of prophylaxis relative
to no prophylaxis
Nussler
et al. (2002)
1250 97 Hypersplenism and enlarged
splenic artery
 Splenic artery ligation (15)
 Splenic artery banding (82)
 Splenectomy (1)
 Portal vein
thrombosis (1)
 Death due to sepsis
and multi-organ
failure (2)
Splenic artery banding
and ligation can prevent
development of SAS;
Splenic artery ligation
was seen to have greater
morbidity and mortality
than banding
Mogl
et al. (2010)
553 98 Hypersplenism, dominant
splenic artery branch relative
to other celiac branches
 Splenic artery ligation (78)
 Splenic artery banding (20)
 SAS (2)
 Splenectomy (1)
 Re-operation for
bleeding due to
ligation (1)
 Biliary tract
complications (3)
 Re-OTLTx (12)
Rate of complications
related to prophylaxis
is lower than that seen
in patients following
embolization treatment
for SAS
Umeda
et al. (2011)
60 30 Randomized Splenic artery embolization
12e18 h
before transplantation
Graft failure due
to small for size
syndrome (1)
Patients with prophylactic
treatment had decreased
blood loss, shorter
operation time,
signiﬁcantly less ascites
post-op, and signiﬁcantly
lower mortality rate
compared to no
prophylaxis group
Wojcicki
et al. (2012)
99 7 Decreased hepatic artery
mean arterial
pressure compared
to radial artery
 Intraoperative splenic artery
ligation (5)
 Arcuate ligament division (1)
 Aortohepatic bypass grafting (1)
None Normalization of arterial
inﬂow pressure to graft (7)
a Patients.
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complications including the need for splenectomy, sepsis and re-
operation for hemorrhage related to arterial ligation (Table 3).
If prophylactic treatment is performed, intra-operative treat-
ment is generally preferred since pre-operative procedures in-
crease morbidity [13]. Selection of an appropriate intra-operative
strategy depends on the status of the recipient common hepatic
artery.
If the common hepatic artery is atrophic, modiﬁed vascular
anastomoses may help prevent SAS. Anastomosing the donor he-
patic artery with the recipient aorta via an iliac artery or with the
splenic artery can be effective in preventing SAS [14]. However,
these techniques are technically demanding and HAT is a potential
complication [12]. In addition, an adequate conduit may not be
immediately available for the interposition graft. If the recipient
hepatic artery is adequate, a traditional donor to recipient anasto-
mosis may be performed and splenic artery banding or ligationmay
be considered for prophylaxis of SAS [12].8. Conclusion
Splenic Artery Syndrome may cause hepatic arterial hypo-
perfusion leading to ischemic biliary lesions and ultimately graft
failure if not detected and treated promptly. Clinical and laboratory
features are non-speciﬁc. The diagnosis is most reliably established
on conventional angiography, though ultimately is only conﬁrmed
by successful treatment. CEUS is a potential non-invasive alterna-
tive diagnostic modality. Minimally invasive interventional tech-
niques are preferred over surgical treatment because of fewer
complications. Identiﬁcation of high-risk candidates with pre-
operative CT may allow preemptive operative strategies or
heightened post-operative surveillance. Hopefully an increased
awareness of Splenic Artery Syndromewill improve outcomes after
orthotopic liver transplantation.Ethical approval
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